Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Gibson, CM; Duffy, D; Korjian, S; Bahit, MC; Chi, G; Alexander, JH; Lincoff, AM; Heise, M; Tricoci, P; Deckelbaum, LI; Mears, SJ; Nicolau, JC; Lopes, RD; Merkely, B; Lewis, BS; Cornel, JH; Trebacz, J; Parkhomenko, A; Libby, P; Sacks, FM; Povsic, TJ; Bonaca, M; Goodman, SG; Bhatt, DL; Tendera, M; Steg, PG; Ridker, PM; Aylward, P; Kastelein, JJP; Bode, C; Mahaffey, KW; Nicholls, SJ; Pocock, SJ; Mehran, R; Harrington, RA, , AEGIS-II, Committees, and, Investigators.
Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
N Engl J Med. 2024; 390(17): 1560-1571. Doi: 10.1056/NEJMoa2400969
Web of Science PubMed FullText FullText_MUG

 

Study Group Members Med Uni Graz:
von Lewinski Dirk
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
BACKGROUND: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear. METHODS: We conducted an international, double-blind, placebo-controlled trial involving patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors. Patients were randomly assigned to receive either four weekly infusions of 6 g of CSL112 or matching placebo, with the first infusion administered within 5 days after the first medical contact for the acute myocardial infarction. The primary end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes from randomization through 90 days of follow-up. RESULTS: A total of 18,219 patients were included in the trial (9112 in the CSL112 group and 9107 in the placebo group). There was no significant difference between the groups in the risk of a primary end-point event at 90 days of follow-up (439 patients [4.8%] in the CSL112 group vs. 472 patients [5.2%] in the placebo group; hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.05; P = 0.24), at 180 days of follow-up (622 patients [6.9%] vs. 683 patients [7.6%]; hazard ratio, 0.91; 95% CI, 0.81 to 1.01), or at 365 days of follow-up (885 patients [9.8%] vs. 944 patients [10.5%]; hazard ratio, 0.93; 95% CI, 0.85 to 1.02). The percentage of patients with adverse events was similar in the two groups; a higher number of hypersensitivity events was reported in the CSL112 group. CONCLUSIONS: Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, NCT03473223.).
Find related publications in this database (using NLM MeSH Indexing)
Aged - administration & dosage
Female - administration & dosage
Humans - administration & dosage
Male - administration & dosage
Middle Aged - administration & dosage
Apolipoprotein A-I - administration & dosage, blood
Cardiovascular Diseases - etiology, metabolism, mortality, prevention & control
Coronary Artery Disease - drug therapy, complications
Double-Blind Method - administration & dosage
Infusions, Intravenous - administration & dosage
Kaplan-Meier Estimate - administration & dosage
Lipoproteins, HDL - blood, metabolism
Myocardial Infarction - complications, drug therapy, metabolism, mortality
Recurrence - administration & dosage
Secondary Prevention - administration & dosage
Stroke - prevention & control
Risk Factors - administration & dosage

© Med Uni Graz • Imprint